Q-omics provides the consensus-scored HNRNPA1P76 profile across patient tissues and cancer cell-line models. HNRNPA1P76 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P76 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, HNRNPA1P76 RNA expression shows 6,993 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRP, KIRC, and LAML as cancer lineages where HNRNPA1P76 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P76 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P76 survival associations across molecular data types. HNRNPA1P76 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P76 RNA expression–survival associations across cancer types. High HNRNPA1P76 expression shows unfavorable associations in KIRP, CHOL, TGCT and UCEC, but favorable associations in UCS and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HNRNPA1P76 RNA expression.
This table summarizes HNRNPA1P76 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P76. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P76 shows lower tumor expression in UCEC and COAD and higher tumor expression in KIRC, KICH, LIHC and KIRP. The KIRC box plot shows higher HNRNPA1P76 RNA expression in tumor versus normal tissue (log2 FC = +0.039, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P76 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P76 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
